- Home
- REI vs PVLA Comparison
REI vs PVLA Comparison
Compare REI & PVLA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REI
- PVLA
- Stock Information
- Founded
- REI 2004
- PVLA 2015
- Country
- REI United States
- PVLA United States
- Employees
- REI N/A
- PVLA N/A
- Industry
- REI Oil & Gas Production
- PVLA Biotechnology: Pharmaceutical Preparations
- Sector
- REI Energy
- PVLA Health Care
- Exchange
- REI Nasdaq
- PVLA Nasdaq
- Market Cap
- REI 241.9M
- PVLA 280.4M
- IPO Year
- REI N/A
- PVLA N/A
- Fundamental
- Price
- REI $0.92
- PVLA $24.46
- Analyst Decision
- REI
- PVLA Strong Buy
- Analyst Count
- REI 0
- PVLA 7
- Target Price
- REI N/A
- PVLA $44.43
- AVG Volume (30 Days)
- REI 2.5M
- PVLA 97.9K
- Earning Date
- REI 05-07-2025
- PVLA 05-15-2025
- Dividend Yield
- REI N/A
- PVLA N/A
- EPS Growth
- REI N/A
- PVLA N/A
- EPS
- REI 0.34
- PVLA N/A
- Revenue
- REI $350,210,849.00
- PVLA N/A
- Revenue This Year
- REI $2.59
- PVLA N/A
- Revenue Next Year
- REI $17.45
- PVLA N/A
- P/E Ratio
- REI $2.71
- PVLA N/A
- Revenue Growth
- REI 2.13
- PVLA N/A
- 52 Week Low
- REI $0.78
- PVLA $6.20
- 52 Week High
- REI $2.06
- PVLA $29.27
- Technical
- Relative Strength Index (RSI)
- REI 45.61
- PVLA N/A
- Support Level
- REI $0.86
- PVLA N/A
- Resistance Level
- REI $0.95
- PVLA N/A
- Average True Range (ATR)
- REI 0.06
- PVLA 0.00
- MACD
- REI 0.02
- PVLA 0.00
- Stochastic Oscillator
- REI 81.47
- PVLA 0.00
About REI Ring Energy Inc.
Ring Energy Inc is an independent exploration and production company based in The Woodlands, Texas and is engaged in oil and natural gas development, production, acquisition, and exploration activities currently focused in the Permian Basin of Texas. The drilling operations of the company target the oil and liquid rich producing formations in the Northwest Shelf, the Central Basin Platform and the Delaware Basin all of which are part of the Permian Basin in Texas.
About PVLA Palvella Therapeutics Inc. Common Stock
Palvella Therapeutics Inc is a late clinical-stage biopharmaceutical company committed to serving individuals suffering from serious, rare genetic skin diseases without approved therapies. The Company's lead product candidate, QTORIN 3.9 percent rapamycin anhydrous gel (QTORIN rapamycin), is based on the Company's patented QTORIN platform. QTORIN rapamycin is in clinical development for two rare genetic skin disorders.